Literature DB >> 24556884

Accidental insertion of dexamethasone implant into the crystalline lens--12 months follow-up.

R Chhabra1, K Kopsidas1, S Mahmood1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24556884      PMCID： PMC4017105          DOI： 10.1038/eye.2014.18

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  4 in total

1.  Repositioning of dexamethasone intravitreal implant (Ozurdex) migrated into the anterior chamber.

Authors:  José I Vela; Jaume Crespí; David Andreu
Journal:  Int Ophthalmol       Date:  2012-07-05       Impact factor: 2.031

2.  Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.

Authors:  Julia A Haller; Francesco Bandello; Rubens Belfort; Mark S Blumenkranz; Mark Gillies; Jeffrey Heier; Anat Loewenstein; Young-Hee Yoon; Marie-Louise Jacques; Jenny Jiao; Xiao-Yan Li; Scott M Whitcup
Journal:  Ophthalmology       Date:  2010-04-24       Impact factor: 12.079

3.  [Anterior chamber migration of intravitreal dexamethasone implant (Ozurdex®) in pseudophakic eyes: report of three cases].

Authors:  A Malclès; H Janin-Manificat; Y Yhuel; A Russo; E Agard; H El Chehab; G Ract Madoux; H Masse; C Burillon; C Dot
Journal:  J Fr Ophtalmol       Date:  2013-01-12       Impact factor: 0.818

4.  Wandering Ozurdex(®) implant.

Authors:  Reema Bansal; Pooja Bansal; Pandurang Kulkarni; Vishali Gupta; Aman Sharma; Amod Gupta
Journal:  J Ophthalmic Inflamm Infect       Date:  2011-09-30
  4 in total
  12 in total

1.  Vitreoretinal surgery for inadvertent intralenticular Ozurdex implant.

Authors:  K Chalioulias; M M K Muqit
Journal:  Eye (Lond)       Date:  2014-08-08       Impact factor: 3.775

2.  Intralenticular Ozurdex® - One Year Later.

Authors:  Kathleen A Regan; Charles R Blake; Zachary L Lukowski; Siva S R Iyer
Journal:  Case Rep Ophthalmol       Date:  2017-12-21

3.  Inadvertent intralenticular Ozurdex removal.

Authors:  Madhurima Roy; Aniruddha Maiti; Sayan Das; Sagnik Surya Das
Journal:  Oman J Ophthalmol       Date:  2022-03-02

4.  Intracrystalline Ozurdex®: therapeutic effect maintained for 18 months.

Authors:  Rodrigo Clemente-Tomás; Delia Hernández-Pérez; Paulina Neira-Ibáñez; Francisco Farías-Rozas; Raúl Torrecillas-Picazo; Vanesa Osorio-Alayo; Antonio M Duch-Samper
Journal:  Int Ophthalmol       Date:  2017-11-30       Impact factor: 2.031

5.  Ozurdex completely located inside a crystallized lens - Results of 14 months.

Authors:  Burhan Baskan; Ayşe Cıcek; Ahmet Gulhan; Medine Gundogan; Sertan Goktas
Journal:  Am J Ophthalmol Case Rep       Date:  2016-08-11

6.  Immortal Ozurdex: A 10-month follow-up of an intralenticular implant.

Authors:  B Poornachandra; Vinod B M Kumar; Chaitra Jayadev; Subashchandra H Dorelli; Naresh Kumar Yadav; Rohit Shetty
Journal:  Indian J Ophthalmol       Date:  2017-03       Impact factor: 1.848

7.  Iatrogenic subretinal injection of Ozurdex® implant and its effect on macular edema.

Authors:  Smita Shriram Karandikar; George J Manayath; Veerappan Saravanan; Siddharth Narendran; Venkatapathy Narendran
Journal:  Oman J Ophthalmol       Date:  2017 May-Aug

8.  Pars plana vitrectomy and re-directing a dexamethasone implant into vitreous cavity following misdirected entry into the crystalline lens.

Authors:  Partha Biswas; Krishnendu Nandi; Sneha Batra; Aniket Ginodia; Preeyam Biswas
Journal:  Indian J Ophthalmol       Date:  2018-07       Impact factor: 1.848

9.  Accidental Intralenticular Injection of Ozurdex® for Branch Retinal Vein Occlusion: Intact Posterior Capsule and Resolution of Macular Edema.

Authors:  Ali Kurt; Ali Hakan Durukan; Murat Küçükevcilioğlu
Journal:  Case Rep Ophthalmol Med       Date:  2019-01-23

10.  Morphological and Functional Outcomes after Intravitreal Dexamethasone Injection for Macular Edema in Patients with Central Vein Occlusion at 48-Week Follow-Up.

Authors:  Cristina Nicula; Dorin Nicula; Anca Rednik; Adriana Bulboaca; Ovidiu Crișan
Journal:  J Ophthalmol       Date:  2020-02-11       Impact factor: 1.909
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.